National Planning Corporation’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

National Planning Corporation’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-6,448	Closed	-$335K	–	1626
2014 Q4	$335K	Sell	6,448 -559	-8%	-$27.4K	0.02%	513
2014 Q3	$327K	Buy	7,007 +928	+15%	+$41.8K	0.02%	530
2014 Q2	$266K	Buy	6,079 +263	+5%	+$10.7K	0.02%	590
2014 Q1	$247K	Buy	+5,816	New	+$249K	0.02%	581

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TAM

Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return

Quantitative Advantage Minnetonka, Minnesota $689M AUM 6.25% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

National Planning Corporation's PBE Position: Q1 2015 in Review

National Planning Corporation sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2015, closing a stake of 6,448 shares — an estimated $335K sold.

National Planning Corporation first reported a position in PBE in Q1 2014 and held it in 4 quarters. The position peaked at $335K in Q4 2014. 87 funds tracked by Wall St. Rank hold PBE as of Q1 2015.

National Planning Corporation reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2015 after selling out during the quarter.
National Planning Corporation sold 6,448 Invesco Biotechnology & Genome ETF shares in Q1 2015, an estimated $335K.
National Planning Corporation first reported a position in Invesco Biotechnology & Genome ETF in Q1 2014 and held it in 4 quarters.
National Planning Corporation's Invesco Biotechnology & Genome ETF position peaked at $335K in Q4 2014.
87 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2015.

Based on National Planning Corporation's 13F filing for Q1 2015, filed 12 May 2015.